https://beonemedaffairs.com/us/congress-resources/ash-2025/mrd-guided-therapy-of-sonrotoclax-bgb-11417-obinutuzumab-o-in-patients-with-treatment-naive-cll-initial-results-from-an-ongoing-phase-1-1b-study-bgb-11417-101/ 2026-05-09T06:18:38+00:00 https://beonemedaffairs.com/us/congress-resources/eha-2025/updated-results-from-the-phase-1-study-of-sonrotoclax-bgb-11417-a-novel-bcl2-inhibitor-in-combination-with-zanubrutinib-for-relapsed-refractory-cll-sll-show-deep-and-durable-responses/ 2026-05-09T13:54:26+00:00 https://beonemedaffairs.com/us/congress-resources/eha-2025/updated-efficacy-and-safety-of-the-bruton-tyrosine-kinase-btk-degrader-bgb-16673-in-patients-pts-with-relapsed-or-refractory-r-r-cll-sll-results-from-the-ongoing-phase-ph-1-cadance-101-study/ 2026-05-09T14:00:44+00:00 https://beonemedaffairs.com/us/congress-resources/eha-2025/updated-efficacy-safety-of-the-bruton-tyrosine-kinase-btk-degrader-bgb-16673-in-patients-with-relapsed-refractory-waldenstrom-macroglobulinemia-wm-ongoing-phase-1-cadance-101-study-results/ 2026-05-09T14:03:40+00:00 https://beonemedaffairs.com/us/congress-resources/eha-2025/combination-of-zanubrutinib-zanu-venetoclax-ven-for-treatment-naive-tn-cll-sll-results-in-sequoia-arm-d/ 2026-05-11T10:04:41+00:00 https://beonemedaffairs.com/us/congress-resources/eha-2025/comparative-efficacy-of-zanubrutinib-versus-fixed-duration-acalabrutinib-plus-venetoclax-for-first-line-treatment-of-chronic-lymphocytic-leukemia-cll-a-matching-adjusted-indirect-comparison-maic-2/ 2026-05-11T10:13:45+00:00 https://beonemedaffairs.com/us/congress-resources/eha-2025/final-analysis-of-a-phase-1-study-of-zanubrutinib-zanu-plus-lenalidomide-len-in-patients-pts-with-relapsed-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl/ 2026-05-11T10:20:53+00:00 https://beonemedaffairs.com/us/congress-resources/eha-2025/real-world-burden-of-disease-treatment-patterns-and-outcomes-in-patients-with-mantle-cell-lymphoma-mcl/ 2026-05-11T10:32:48+00:00 https://beonemedaffairs.com/us/congress-resources/eha-2025/real-world-comparative-effectiveness-of-first-line-bruton-tyrosine-kinase-inhibitors-in-patients-with-chronic-lymphocytic-leukemia/ 2026-05-11T10:40:01+00:00 https://beonemedaffairs.com/us/congress-resources/eha-2025/real-world-treatment-utilization-patterns-discontinuation-and-healthcare-resource-utilization-of-first-line-bruton-tyrosine-kinase-inhibitors-in-chronic-lymphocytic-leukemia-age-related-disparity/ 2026-05-11T10:43:46+00:00 https://beonemedaffairs.com/us/congress-resources/eha-2025/real-world-zanubrutinib-treatment-patterns-in-mantle-cell-lymphoma-among-us-community-oncology-patients-with-prior-bruton-tyrosine-kinase-inhibitor-therapy/ 2026-05-11T10:45:46+00:00 https://beonemedaffairs.com/us/congress-resources/eha-2025/risk-of-hypertension-in-patients-newly-diagnosed-with-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-cll-sll-and-treated-with-covalent-bruton-tyrosine-kinase-inhibitors-a-real-world-study/ 2026-05-11T10:48:31+00:00 https://beonemedaffairs.com/us/congress-resources/eha-2025/sequoia-5-year-follow-up-in-arm-c-frontline-zanubrutinib-monotherapy-in-patients-with-del17p-and-treatment-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-cll-sll/ 2026-05-11T10:52:57+00:00 https://beonemedaffairs.com/us/congress-resources/eha-2025/serious-infections-in-patients-with-cll-sll-treated-with-combination-venetoclax-and-obinutuzumab-compared-with-those-treated-with-zanubrutinib-a-real-world-study/ 2026-05-11T10:54:47+00:00 https://beonemedaffairs.com/us/congress-resources/eha-2025/sonrotoclax-monotherapy-for-treatment-of-patients-with-relapsed-refractory-cll-data-from-an-ongoing-phase-1-1b-study-bgb-11417-101/ 2026-05-11T10:57:51+00:00 https://beonemedaffairs.com/us/congress-resources/eha-2025/updated-interim-results-of-sonrotoclax-dexamethasone-in-patients-with-t1114-positive-relapsed-refractory-multiple-myeloma-an-all-oral-treatment/ 2026-05-11T11:01:36+00:00 https://beonemedaffairs.com/us/congress-resources/eha-2025/updated-safety-antileukemic-activity-data-of-sonrotoclax-bgb-11417-a-potent-and-selective-bcl2-inhibitor-in-treatment-naive-patients-with-acute-myeloid-leukemia-unfit-for-intensive-chemotherapy/ 2026-05-11T11:04:09+00:00 https://beonemedaffairs.com/us/congress-resources/eha-2025/primary-analysis-results-of-novel-bcl2-inhibitor-sonrotoclax-bgb-11417-monotherapy-in-patients-with-relapsed-refractory-b-cell-malignancies/ 2026-05-11T11:09:40+00:00 https://beonemedaffairs.com/us/congress-resources/eha-2025/combination-treatment-with-novel-bcl2-inhibitor-sonrotoclax-bgb-11417-and-zanubrutinib-induces-high-rate-of-complete-remission-for-patients-with-relapsed-refractory-mantle-cell-lymphoma/ 2026-05-11T11:12:26+00:00 https://beonemedaffairs.com/us/congress-resources/esmo-2025/a-first-in-human-phase-1-study-of-bgb-15025-hematopoietic-progenitor-kinase-1-hpk1-inhibitor-as-monotherapy-and-in-combination-combo-with-tislelizumab-tis-anti-pd-1-antibody-in-patients-pts/ 2026-05-11T11:31:20+00:00 https://beonemedaffairs.com/us/congress-resources/esmo-2025/first-in-human-phase-1-study-of-bgb-26808-hematopoietic-progenitor-kinase-1-hpk1-inhibitor-%c2%b1-tislelizumab-tis-anti-pd-1-in-advanced-solid-tumors-sts/ 2026-05-11T11:32:23+00:00 https://beonemedaffairs.com/us/congress-resources/esmo-2025/tislelizumab-tis-with-or-without-capecitabine-cap-continuation-in-patients-pts-with-gastric-or-gastro-oesophageal-junction-cancer-gc-gejc-a-post-hoc-analysis-of-rationale-305/ 2026-05-11T11:35:25+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/mrd-guided-therapy-of-sonrotoclax-bgb-11417-obinutuzumab-o-in-patients-with-treatment-naive-cll-initial-results-from-an-ongoing-phase-1-1b-study-bgb-11417-101-2/ 2026-05-11T11:52:41+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/updated-efficacy-and-safety-results-of-the-bruton-tyrosine-kinase-btk-degrader-bgb-16673-in-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-cll-sll-from-t/ 2026-05-11T11:57:04+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/initial-phase-1b-2-study-results-with-sonrotoclax-bgb-11417-in-combination-with-carfilzomib-and-dexamethasone-in-patients-with-t1114-positive-relapsed-refractory-multiple-myeloma/ 2026-05-11T11:58:56+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/preliminary-results-from-a-phase-1-1b-first-in-human-study-of-bgb-21447-a-next-generation-bcl2-inhibitor-in-patients-with-b-cell-non-hodgkin-lymphoma/ 2026-05-11T13:49:21+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/updated-efficacy-and-safety-results-of-the-bruton-tyrosine-kinase-degrader-bgb-16673-in-patients-with-relapsed-refractory-indolent-non-hodgkin-lymphoma-from-the-ongoing-phase-1-cadance-101-study/ 2026-05-11T13:51:24+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/updated-efficacy-and-safety-results-of-the-bruton-tyrosine-kinase-degrader-bgb-16673-in-patients-with-relapsed-refractory-waldenstrom-macroglobulinemia-from-the-ongoing-phase-1-cadance-101-study/ 2026-05-11T13:53:41+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/zanubrutinib-obinutuzumab-sonrotoclax-in-patients-with-treatment-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-tn-cll-sll-initial-results-from-an-ongoing-phase-1-1b-study-bgb-1/ 2026-05-11T14:00:21+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/primary-analysis-of-a-multicenter-open-label-phase-2-study-of-sonrotoclax-bgb-11417-monotherapy-in-patients-with-relapsed-refractory-r-r-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphom/ 2026-05-11T14:05:12+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/cadance-104-an-ongoing-open-label-phase-1b-2-master-protocol-study-of-bruton-tyrosine-kinase-degrader-bgb-16673-in-combination-with-other-agents-in-patients-with-relapsed-refractory-b-cell-malignan/ 2026-05-11T14:09:16+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/a-phase-3-randomized-open-label-multicenter-study-of-sonrotoclax-bgb-11417-plus-anti-cd20-antibody-therapies-vs-venetoclax-plus-rituximab-in-patients-with-relapsed-refractory-chronic-lymphocytic/ 2026-05-11T14:11:10+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/real-world-treatment-patterns-and-biomarker-utilization-among-patients-aged-%e2%89%a565-years-with-cll-sll-from-2020-to-2024/ 2026-05-11T14:12:40+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/patient-preferences-and-factors-affecting-patient-treatment-decisions-for-chronic-lymphocytic-leukemia-cll-in-japan/ 2026-05-11T14:14:12+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/impact-of-testing-for-genetic-markers-on-treatment-selection-and-clinical-outcomes-among-patients-with-chronic-lymphocytic-leukemia/ 2026-05-11T14:15:54+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/chemo-%c2%b1-immunotherapy-remains-utilized-for-chronic-lymphocytic-lymphoma-in-the-real-world-practice-unmet-needs-treatment-patterns-and-age-disparities-in-the-united-states/ 2026-05-11T14:32:52+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/matching-adjusted-indirect-comparison-of-efficacy-of-zanubrutinib-vs-ibrutinib-for-the-treatment-of-relapsed-refractory-mantle-cell-lymphoma/ 2026-05-11T14:36:14+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/cadance-304-a-phase-3-open-label-randomized-study-to-evaluate-the-safety-and-efficacy-of-bruton-tyrosine-kinase-degrader-bgb-16673-compared-with-pirtobrutinib-in-patients-with-relapsed-refractory-c/ 2026-05-11T14:42:34+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/changes-in-real-world-treatment-patterns-over-time-by-patient-characteristics-and-time-burden-of-treatment-in-cll-sll/ 2026-05-11T20:21:43+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/real-world-treatment-patterns-and-patient-characteristics-of-venetoclax-combination-time-limited-therapy-for-chronic-lymphocytic-leukemia/ 2026-05-11T20:22:00+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/progression-free-survival-pfs-in-patients-with-low-health-related-quality-of-life-hrqol-treated-with-zanubrutinib-versus-ibrutinib-monotherapy-post-hoc-analysis-of-the-alpine-trial/ 2026-05-11T20:22:43+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/mediators-of-racial-and-ethnic-inequities-in-access-to-front-line-therapies-for-chronic-lymphocytic-leukemia-in-the-united-states-a-real-world-evidence-study/ 2026-05-11T20:23:02+00:00 https://beonemedaffairs.com/us/congress-resources/iwcll-2025/safety-and-efficacy-of-zanubrutinib-in-a-subgroup-of-older-patients-%e2%89%a575-years-with-treatment-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-from-the-sequoia-study/ 2026-05-11T20:48:03+00:00 https://beonemedaffairs.com/us/congress-resources/iwcll-2025/estimating-the-cardiac-deaths-associated-with-treating-chronic-lymphocytic-leukemia-with-ibrutinib-versus-zanubrutinib-in-the-united-states/ 2026-05-11T20:48:17+00:00 https://beonemedaffairs.com/us/congress-resources/iwcll-2025/comparative-efficacy-of-zanubrutinib-versus-fixed-duration-acalabrutinib-plus-venetoclax-for-first-line-treatment-of-chronic-lymphocytic-leukemia-cll-a-matching-adjusted-indirect-comparison-maic/ 2026-05-11T20:48:38+00:00 https://beonemedaffairs.com/us/congress-resources/iwcll-2025/combination-of-zanubrutinib-venetoclax-for-treatment-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-results-in-sequoia-arm-d/ 2026-05-11T20:48:50+00:00 https://beonemedaffairs.com/us/congress-resources/iwcll-2025/a-network-meta-analysis-nma-of-efficacy-of-zanubrutinib-versus-fixed-duration-acalabrutinib-plus-venetoclax-in-treatment-naive-tn-chronic-lymphocytic-leukemia-cll/ 2026-05-11T20:49:06+00:00 https://beonemedaffairs.com/us/congress-resources/eha-2025/updated-safety-and-efficacy-results-of-a-phase-1-study-of-the-novel-bcl2-inhibitor-sonrotoclax-bgb-11417-for-relapsed-refractory-waldenstroms-macroglobulinemia/ 2026-05-11T20:50:08+00:00 https://beonemedaffairs.com/us/congress-resources/eha-2025/updated-safety-and-antileukemic-activity-data-for-sonrotoclax-bgb-11417-a-potent-and-selective-bcl2-inhibitor-in-patients-with-relapsed-refractory-acute-myeloid-leukemia/ 2026-05-11T20:50:15+00:00 https://beonemedaffairs.com/us/congress-resources/iwcll-2025/sequoia-5-year-follow-up-in-arm-c-frontline-zanubrutinib-monotherapy-in-patients-with-del17p-and-treatment-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma/ 2026-05-11T20:54:57+00:00 https://beonemedaffairs.com/us/wp-content/uploads/sites/3/2026/05/congress-banner.png https://beonemedaffairs.com/us/congress-resources/asco-2026/real-world-insights-on-post-cbtki-landscape-in-mcl/ 2026-05-12T12:42:39+00:00 https://beonemedaffairs.com/us/congress-resources/asco-2026/comparison-of-treatment-survival-outcomes-with-zanu-acala-monotherapy-in-rr-mcl-in-us/ 2026-05-12T12:48:52+00:00 https://beonemedaffairs.com/us/congress-resources/aacr-2026/pharmacodynamic-pd-characterization-of-bgb-24714-a-second-mitochondrial-derived-activator-of-caspases-smac-mimetic-in-a-first-in-human-study-in-solid-tumors/ 2026-05-12T12:54:13+00:00 https://beonemedaffairs.com/us/congress-resources/aacr-2026/a-phase-1-study-of-bgb-24714-a-second-mitochondrial-derived-activator-of-caspases-smac-mimetic-as-monotherapy-or-in-combination-with-chemotherapy-or-concurrent-chemoradiotherapy-in-solid-tumors/ 2026-05-12T12:54:49+00:00 https://beonemedaffairs.com/us/congress-resources/aacr-2026/exploratory-biomarker-analysis-of-the-phase-3-rationale-305-trial-first-line-1l-tislelizumab-tis-chemotherapy-ct-vs-placebo-pbo-ct-for-advanced-gastric-cancer-gastro-oesophageal-junction/ 2026-05-12T12:55:16+00:00 https://beonemedaffairs.com/us/congress-resources/aacr-2026/a-phase-2-study-of-tislelizumab-tis-investigational-agents-as-first-line-1l-treatment-in-recurrent-and-or-metastatic-head-and-neck-squamous-cell-carcinoma-r-m-hnscc/ 2026-05-12T12:55:49+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/sustained-efficacy-of-zanubrutinib-zanu-vs-bendamustine-rituximab-br-in-treatment-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-tn-sll-cll-with-continued-favorable-survival-in/ 2026-05-12T19:37:13+00:00 https://beonemedaffairs.com/us/congress-resources/eha-2025/factors-influencing-individualized-treatment-selection-in-cll-anne-sophie-michallet/ 2026-05-12T19:40:14+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/zanubrutinib-venetoclax-for-treatment-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-cll-sll-including-patients-with-del17p-and-or-tp53-mutation-and-unmutated-immunoglobulin-heav/ 2026-05-12T19:40:54+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/long-term-results-of-patients-receiving-zanubrutinib-in-the-phase-3-alpine-study-confirm-sustained-benefit-of-zanubrutinib-in-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-ly/ 2026-05-12T19:45:27+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/evaluation-of-factors-from-established-prognostic-models-in-patients-with-chronic-lymphocytic-leukemia-cll-treated-with-zanubrutinib-a-post-hoc-analysis-of-two-phase-3-studies-sequoia-and-alpine/ 2026-05-12T19:45:54+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/final-analysis-of-the-randomized-phase-2-rosewood-study-of-zanubrutinib-obinutuzumab-vs-obinutuzumab-monotherapy-in-patients-with-relapsed-refractory-follicular-lymphoma/ 2026-05-12T19:47:02+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/symptom-based-progression-free-survival-s-pfs-as-a-clinically-relevant-and-patient-centric-endpoint-in-chronic-lymphocytic-leukemia-cll-small-lymphocytic-lymphoma-sll-results-from-the-alpine-tr/ 2026-05-12T19:47:21+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/zanubrutinib-is-well-tolerated-and-effective-in-acalabrutinib-intolerant-patients-with-b-cell-malignancies-a-long-term-follow-up/ 2026-05-12T19:47:39+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/number-needed-to-treat-to-avoid-progression-or-death-zanubrutinib-vs-other-covalent-bruton-tyrosine-kinase-inhibitors-in-relapsed-refractory-chronic-lymphocytic-leukemia/ 2026-05-12T19:48:04+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/outcomes-during-btki-treatment-for-chronic-lymphocytic-leukemia-insights-from-remote-therapeutic-monitoring/ 2026-05-12T19:48:20+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/treatment-patterns-and-outcomes-among-patients-treated-with-second-generation-btk-inhibitors-in-cll/ 2026-05-12T19:48:35+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/sonrotoclax-bgb-11417-monotherapy-in-patients-with-relapsed-refractory-r-r-mantle-cell-lymphoma-mcl-previously-treated-with-a-bruton-tyrosine-kinase-btk-inhibitor-early-results-from-a-phase-1/ 2026-05-12T19:50:46+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/frontline-treatment-of-sonrotoclax-bgb-11417-and-zanubrutinib-for-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-cll-sll-demonstrates-high-undetectable-minimal-residual-disease-umrd-rat/ 2026-05-12T19:51:07+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/preliminary-efficacy-and-safety-of-the-bruton-tyrosine-kinase-degrader-bgb-16673-in-patients-with-relapsed-refractory-richter-transformation-results-from-the-ongoing-phase-1-cadance-101-study/ 2026-05-12T19:51:48+00:00 https://beonemedaffairs.com/us/congress-resources/ash-2025/bgb-3111-218-single-arm-open-label-multicenter-study-of-the-bruton-tyrosine-kinase-btk-inhibitor-zanubrutinib-zanu-in-patients-with-cd79b-mutated-relapsed-refractory-r-r-diffuse-large-b-cell/ 2026-05-12T19:52:03+00:00 https://beonemedaffairs.com/us/congress-resources/asco-2026/real-world-treatment-and-survival-outcomes-zanu-acala-monotherapy-in-tn-cll-in-us/ 2026-05-15T14:27:45+00:00 https://beonemedaffairs.com/us/congress-resources/asco-2026/phase-1-bgb-b2033-monotherapy-in-advanced-or-metastatic-solid-tumors/ 2026-05-18T14:41:53+00:00 https://beonemedaffairs.com/us/congress-resources/asco-2026/asco-2026-first-in-human-study-of-bg-c9074-in-advanced-solid-tumors/ 2026-05-18T14:45:55+00:00 https://beonemedaffairs.com/us/congress-resources/asco-2026/herizon-gea-01-pd-l1-subgroup-analysis-zanidatamab-chemotherapy-tislelizumab-in-her2-mgea/ 2026-05-18T14:49:58+00:00 https://beonemedaffairs.com/us/congress-resources/asco-2026/rationale-305-quality-adjusted-survival-for-tislelizumab-ct-in-gastric-gej-adenocarcinoma/ 2026-05-18T14:51:50+00:00 https://beonemedaffairs.com/us/congress-resources/asco-2026/rationale-315-post-hoc-analysis-of-event-free-survival-with-tislelizumab-and-neoadjuvant-ct/ 2026-05-18T14:54:28+00:00 https://beonemedaffairs.com/us/congress-resources/asco-2026/advantig-105-biomarker-analysis-of-ociperlimab-plus-tislelizumab-in-pd-l1-positive-nsclc/ 2026-05-18T14:56:21+00:00 https://beonemedaffairs.com/us/congress-resources/asco-2026/phase-1-study-bgb-a3055-with-or-without-tislelizumab-in-solid-tumors/ 2026-05-18T14:58:05+00:00 https://beonemedaffairs.com/us/congress-resources/asco-2026/adjusted-ideal-body-weight-dosing-in-bg-c9074-pharmacokinetics-efficacy-safety/ 2026-05-18T15:01:27+00:00 https://beonemedaffairs.com/us/congress-resources/asco-2026/herizon-gea-01-gi-adverse-events-with-zanidatamab-chemotherapy-tislelizumab-her2-mgea/ 2026-05-18T15:04:17+00:00 https://beonemedaffairs.com/us/congress-resources/asco-2026/real-world-impact-of-atrial-fibrillation-afib-on-cardiovascular-cv-outcomes-and-healthcare-resource-utilization-hcru-in-patients-with-chronic-lymphocytic-leukemia-cll/ 2026-05-19T09:40:11+00:00 https://beonemedaffairs.com/us/congress-resources/asco-2026/real-world-outcomes-in-medicare-beneficiaries-treated-with-first-line-btkis-for-cll/ 2026-05-19T09:40:26+00:00 https://beonemedaffairs.com/us/congress-resources/asco-2026/sequoia-subsequent-therapies-and-time-to-pfs2-in-treatment-naive-cll-sll/ 2026-05-19T09:40:40+00:00 https://beonemedaffairs.com/us/congress-resources/asco-2026/phase-3-celestial-tncll-2-sonrotoclax-zanubrutinib-vs-venetoclax-acalabrutinib/ 2026-05-19T09:40:53+00:00 https://beonemedaffairs.com/us/congress-resources/asco-2026/first-line-treatment-of-cll-sll-with-sonrotoclax-zanubrutinib/ 2026-05-19T09:41:04+00:00 https://beonemedaffairs.com/us/congress-resources/asco-2026/first-disclosure-of-frontline-treatment-1l-tx-with-the-selective-cdk4-inhibitor-bgb-43395-in-combination-with-letrozole-for-metastatic-hr-her2%e2%88%92-breast-cancer-bc-a-phase-1-safety-expansio/ 2026-05-19T09:41:16+00:00